ARASENS: Darolutamide for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Description: Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of the ARASENS study, which is a phase 3 trial on the use of darolutamide for men with metastatic hormone-sensitive prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract #TPS5092: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Shared By : AnnualMeeting2017
Posted on : 06/02/17
Added : 6 months ago
Category : Prostate Cancer


Nothing found.

More From AnnualMeeting2017

Nothing found.